ASX:PAR Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Paradigm Biopharmaceuticals Stock (ASX:PAR) 30 days 90 days 365 days Advanced Chart Get PAR alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.81 million shsAverage VolumeN/AMarket Capitalization$196.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewParadigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.Read More… Receive PAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PAR Stock News HeadlinesBiopharmaceuticals Market Forecast Report 2025-2034: Oncology Segment Captured 30.9% Share in 2024 Amid Surge in Targeted Cancer TherapiesMay 16 at 10:45 PM | finance.yahoo.comCressey & Company Announces Partnership with Leading Hospice Provider, Paradigm HealthMay 12, 2025 | finance.yahoo.comThe $100 Backdoor Into Musk’s New AI EmpireElon Musk’s “Final Move” could change everything in AI—and while average investors can’t get a stake in it directly, there’s a surprising backdoor in. One former Wall Street CEO just revealed a publicly traded company tied to Musk’s secretive project. You can get in for as little as $100—no risky tech plays or deep industry knowledge required.May 18, 2025 | Behind the Markets (Ad)Paradigm Signs ‘Virgin River’ & ‘The Good Doctor’ Director Felipe RodriguezMay 9, 2025 | msn.comIs Paradigm Biopharmaceuticals (ASX:PAR) In A Good Position To Invest In Growth?March 30, 2025 | finance.yahoo.comAdvanced Clinical chosen as CRO for Paradigm’s Phase III osteoarthritis trialFebruary 4, 2025 | msn.comParadigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy from Bell PotterFebruary 2, 2025 | markets.businessinsider.comParadigm for Parity® Names Former CEO Sandra Quince as President of Board of DirectorsJanuary 15, 2025 | finance.yahoo.comSee More Headlines PAR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Paradigm Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryComputer Hardware Current SymbolASX:PAR CIKN/A Webwww.paradigmbiopharma.com Phone61 3 9629 5566FaxN/AEmployees1,480Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,650,000.00 Net Margins-89,138.58% Pretax MarginN/A Return on Equity-203.64% Return on Assets-86.16% Debt Debt-to-Equity Ratio1.01 Current Ratio7.22 Quick Ratio5.93 Sales & Book Value Annual Sales$79,224.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow6.44 Book ValueA$0.08 per share Price / BookN/AMiscellaneous Outstanding Shares350,360,000Free FloatN/AMarket Cap$196.66 million OptionableNot Optionable Beta0.94 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (ASX:PAR) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Two drop-dead simple ways to play the gold boomIf you take a few minutes to check out the short research briefing Mark & I have put together, I’m confident y...Eagle Publishing | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Paradigm Biopharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Paradigm Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PAR Stock Free PAR Stock Alerts